AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Apr 30, 2021
31637_dirs_2021-04-30_831adf84-52b4-4ef7-ad5b-2db415a8751f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-04-28
Reporting Person: SATO VICKI L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-28 | Common Stock | S | 381 | $60.706 | Disposed | 137040 | Direct |
| 2021-04-28 | Common Stock | S | 597 | $62.047 | Disposed | 136443 | Direct |
| 2021-04-28 | Common Stock | S | 688 | $63.034 | Disposed | 135755 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $60.36 to $60.985 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 3,253 restricted stock units.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $61.47 to $62.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $62.73 to 63.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.